Stryker Co. (NYSE:SYK) Shares Acquired by Catalina Capital Group LLC

Catalina Capital Group LLC increased its stake in Stryker Co. (NYSE:SYK) by 8.4% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 1,656 shares of the medical technology company’s stock after buying an additional 129 shares during the quarter. Catalina Capital Group LLC’s holdings in Stryker were worth $563,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of SYK. Burkett Financial Services LLC acquired a new stake in Stryker in the 4th quarter valued at about $25,000. Rogco LP acquired a new stake in Stryker during the 4th quarter worth about $30,000. DSM Capital Partners LLC acquired a new stake in Stryker during the 4th quarter worth about $34,000. Central Pacific Bank Trust Division acquired a new stake in Stryker during the 1st quarter worth about $39,000. Finally, Private Wealth Management Group LLC acquired a new stake in Stryker during the 4th quarter worth about $40,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity

In related news, CFO Glenn S. Boehnlein sold 20,000 shares of the business’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $333.00, for a total transaction of $6,660,000.00. Following the sale, the chief financial officer now directly owns 2,852 shares in the company, valued at approximately $949,716. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Stryker news, CFO Glenn S. Boehnlein sold 20,000 shares of the company’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $333.00, for a total value of $6,660,000.00. Following the transaction, the chief financial officer now directly owns 2,852 shares in the company, valued at approximately $949,716. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 190,000 shares of the company’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $323.46, for a total value of $61,457,400.00. Following the completion of the transaction, the director now owns 3,316,608 shares in the company, valued at $1,072,790,023.68. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Stock Up 0.7 %

Shares of NYSE SYK traded up $2.57 during midday trading on Friday, hitting $353.29. 960,593 shares of the stock traded hands, compared to its average volume of 1,306,913. The company has a market cap of $134.59 billion, a PE ratio of 40.33, a P/E/G ratio of 2.61 and a beta of 0.89. Stryker Co. has a one year low of $249.98 and a one year high of $361.41. The business has a 50 day moving average price of $335.90 and a two-hundred day moving average price of $340.98. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.95 and a current ratio of 1.68.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.79 by $0.02. Stryker had a return on equity of 22.89% and a net margin of 16.12%. The company had revenue of $5.42 billion for the quarter, compared to analysts’ expectations of $5.40 billion. During the same quarter in the previous year, the firm earned $2.54 earnings per share. Stryker’s quarterly revenue was up 8.5% on a year-over-year basis. On average, equities analysts predict that Stryker Co. will post 11.99 EPS for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be given a dividend of $0.80 per share. The ex-dividend date is Monday, September 30th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.91%. Stryker’s dividend payout ratio is presently 36.53%.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on SYK shares. Robert W. Baird upped their target price on Stryker from $367.00 to $378.00 and gave the company an “outperform” rating in a report on Wednesday, May 1st. Needham & Company LLC upped their target price on Stryker from $392.00 to $393.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Piper Sandler upped their target price on Stryker from $375.00 to $380.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Barclays upped their target price on Stryker from $374.00 to $402.00 and gave the company an “overweight” rating in a report on Thursday, August 1st. Finally, StockNews.com upgraded Stryker from a “hold” rating to a “buy” rating in a report on Thursday, July 11th. Four equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $373.11.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.